Skip to main content

Dexcom Value Stock - Dividend - Research Selection

Dexcom

ISIN: US2521311074 , WKN: A0D9T1

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Oscar Health, Penumbra, DexCom, Merit Medical Systems, and HCA Healthcare Shares Are Falling, What You Need To Know

2025-09-10
A number of stocks fell in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading.

DexCom, Inc. (DXCM) Presents At Baird Global Healthcare Conference 2025 Transcript

2025-09-10
Get the latest insights from DexCom's 2025 strategy, CGM market growth, and upcoming

Dexcom Launches Its First Open Call to Uncover the Next Diabetes Advocates Ahead of World Diabetes Day

2025-09-10
SAN DIEGO & BURNABY, British Columbia, September 10, 2025--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of its first open call in the U.S. and Canada in search of the next diabetes advocates. Those selected will experience a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale this World Diabetes Day (Nov. 14) and beyond.

How Is DexCom's Performance Compared to Other Medical Device Companies?

2025-09-09
DexCom has outperformed the broader medical devices industry over the past year, and analysts remain strongly bullish on the stock’s prospects.

Sector Update: Health Care Stocks Softer Late Afternoon

2025-09-08
Health care stocks declined late Monday afternoon, with the NYSE Health Care Index and the Health Ca

Why DexCom (DXCM) Shares Are Sliding Today

2025-09-08
Shares of medical device company DexCom (NASDAQ:DXCM) fell 2% in the morning session after Oppenheimer downgraded the stock to Perform from a previous Outperform rating.

Why DexCom (DXCM) Stock Is Up Today

2025-09-04
Shares of medical device company DexCom (NASDAQ:DXCM) jumped 3.3% in the afternoon session after company executives provided an optimistic outlook at the Wells Fargo Healthcare Conference on Wednesday.

Dexcom to lay off about 350 people

2025-09-04
The diabetes technology company said the cuts are part of broader changes to its structure, including eliminating operations roles in San Diego and shifting those positions to Arizona.

DexCom, Inc. (DXCM) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)

2025-09-03
Discover DexCom's future growth plans, product innovations, and market outlook shared at

DexCom Inc. stock underperforms Tuesday when compared to competitors

2025-09-02
DexCom Inc. stock underperforms Tuesday when compared to competitors